Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
Although most radiology organizations agree that [18F]FDG PET/CT can provide valuable information in these patients post-treatment, their recommendations differ on its use.
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
The deal will create a Therapy Command Center to support the study and use of theranostics across Massachusetts General Hospital and its affiliated centers in bordering states.
Scientists believe this is the first series demonstrating a significant survival difference in patients monitored with an intensive follow-up strategy via 18F-fludeoxyglucose–positron emission tomography.
Given the approach’s “superior prognostic value,” experts urged for the incorporation of tau PET into routine clinical evaluation in memory care clinics.
This year the Henry N. Wagner Jr., Image of the Year is actually a group of images displaying the efficacy of a 68Ga-DOTA-5G and 177Lu-DOTA-ABM-5G theranostic pairing that improves the detection and treatment of metastatic pancreatic cancer.
According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.